• Globus Medical (Audubon, Pennsylvania) reported the introduction of NuBone Osteoinductive bone graft product line, a 100% allograft tissue product, composed of an osteoinductive demineralized bone matrix (DBM) combined with a unique cortical bone gelatin carrier. The first two products in the line to be released are NuBone DBM Putty and NuBone DBM Gel, developed for use in spinal fusion, trauma, and reconstructive bone grafting procedures. Globus Medical is a spinal implant manufacturer.

• Endosense (Geneva, Switzerland) reported the presentation of data as part of the abstract "Novel Radiofrequency Ablation Catheter with Contact Force Sensor Predicts Lesion Size and Incidence of Steam Pop in Canine Model" at the annual 2007 scientific sessions of the Heart Rhythm Society (Washington) in Denver. Tacticath, the Endosense catheter, demonstrated a statistically significant correlation between force and the key characteristics of the lesion: volume, depth, and surface. Since effective radio frequency lesion-making depends critically upon contact, real time assessment of contact force is extremely important. Endosense assists in the adoption of percutaneous catheter ablation for the treatment of atrial fibrillation.

• OMRIX Biopharmaceuticals (New York) reported FDA approval of its supplemental Biologics License Application (sBLA) to market its liquid fibrin sealant, Evicel, in vascular surgery. Evicel is a bovine and aprotinin-free fibrin sealant. It is fast (ready to use in less than one minute after thawing) and forms a clear, stable clot that anchors firmly to the bleeding site. Evicel is currently indicated as an adjunct to hemostasis for use in patients undergoing liver or vascular surgery, when control of bleeding by standard surgical techniques is ineffective or impractical.